Hostname: page-component-848d4c4894-ndmmz Total loading time: 0 Render date: 2024-06-06T00:33:32.863Z Has data issue: false hasContentIssue false
  • English
  • Français

The role of inflammatory biomarkers in CHD-associated pulmonary hypertension in children

Published online by Cambridge University Press:  16 June 2016

Gokcen Oz-Tuncer ,
Rana Olgunturk ,
Ayhan Pektas ,
Erman Cilsal ,
Serdar Kula ,
Deniz A. Oguz ,
Sedef F. Tunaoglu ,
Ozge T. Pasaoglu  and
Hatice Pasaoglu
Gokcen Oz-Tuncer
Affiliation:
Department of Pediatric Neurology, Ankara University Medical Faculty Hospital, Ankara, Turkey
Rana Olgunturk
Affiliation:
Department of Pediatric Cardiology, Medical Faculty Hospital, Gazi University, Ankara, Turkey
Ayhan Pektas*
Affiliation:
Department of Pediatric Cardiology, Medical Faculty Hospital, Afyon Kocatepe University, Afyonkarahisar, Turkey
Erman Cilsal
Affiliation:
Department of Pediatric Cardiology, Adana Numune Research and Education Hospital, Adana, Turkey
Serdar Kula
Affiliation:
Department of Pediatric Cardiology, Medical Faculty Hospital, Gazi University, Ankara, Turkey
Deniz A. Oguz
Affiliation:
Department of Pediatric Cardiology, Medical Faculty Hospital, Gazi University, Ankara, Turkey
Sedef F. Tunaoglu
Affiliation:
Department of Pediatric Cardiology, Medical Faculty Hospital, Gazi University, Ankara, Turkey
Ozge T. Pasaoglu
Affiliation:
Department of Biochemistry, Medical Faculty Hospital, Gazi University, Ankara, Turkey
Hatice Pasaoglu
Affiliation:
Department of Biochemistry, Medical Faculty Hospital, Gazi University, Ankara, Turkey
*
Correspondence to: A. Pektas, M.D, Selcuklu Mah. Adnan Kahveci Cad. No: 16/2 D:4 03200, Afyonkarahisar, Turkey. Tel: +902 722 463 333, +905 333 452 458; Fax: +902 722 463 322; E-mail: drayhanpektas@hotmail.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective

The present study aims to identify the role of inflammatory markers such as C-reactive protein, interleukin-6, and fractalkine in CHD-associated pulmonary hypertension in children.

Methods

This is a prospective review of 37 children with CHD-related pulmonary hypertension, 21 children with congenital heart defects, and 22 healthy children.

Results

Serum C-reactive protein and interleukin-6 levels were significantly higher in the children with CHD-related pulmonary hypertension (respectively, p=0.049 and 0.026). Serum C-reactive protein concentrations correlated negatively with ejection fraction (r=−0.609, p=0.001) and fractional shortening (r=−0.452, p=0.007) in the pulmonary hypertension group. Serum fractalkine concentrations correlated negatively with ejection fraction (r=−0.522, p=0.002) and fractional shortening (r=−0.395, p=0.021) in the children with pulmonary hypertension. Serum interleukin-6 concentrations also correlated negatively with Qs (r=−0.572, p=0.021), positively with Rs (r=0.774, p=0.001), and positively with pulmonary wedge pressure (r=0.796, p=0.006) in the pulmonary hypertension group. A cut-off value of 2.2 IU/L for C-reactive protein was able to predict pulmonary hypertension with 77.5% sensitivity and 77.5% specificity. When the cut-off point for interleukin-6 concentration was 57.5 pg/ml, pulmonary hypertension could be predicted with 80% sensitivity and 75% specificity.

Conclusion

Inflammation is associated with the pathophysiology of pulmonary hypertension. The inflammatory markers C-reactive protein and interleukin-6 may have a role in the clinical evaluation of paediatric pulmonary hypertension related to CHDs.

Keywords

BiomarkerCHDinflammationpulmonary hypertension
Type
Original Articles
Information
Cardiology in the Young , Volume 27 , Issue 2 , March 2017 , pp. 255 - 260
Copyright
© Cambridge University Press 2016 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Beghetti, M, Berger, RM. The challenges in paediatric pulmonary arterial hypertension. Eur Respir Rev 2014; 23: 498–504.Google Scholar
2. Takatsuki, S, Ivy, DD. Current challenges in pediatric pulmonary hypertension. Semin Respir Crit Care Med 2013; 34: 627–644.CrossRefGoogle ScholarPubMed
3. Rosenzweig, EB, Feinstein, JA, Humpl, T, et al. Pulmonary arterial hypertension in children: diagnostic work-up andchallenges. Prog Pediatr Cardiol 2009; 27: 4–11.CrossRefGoogle Scholar
4. Beghetti, M, Berger, RM, Schulze-Neick, I, et al. Diagnostic evaluation of paediatric pulmonary hypertension in current clinical practice. Eur Respir J 2013; 42: 689–700.CrossRefGoogle ScholarPubMed
5. Jone, PN, Ivy, DD. Echocardiography in pediatric pulmonary hypertension. Front Pediatr 2014; 2: 124.Google Scholar
6. El Chami, H, Hassoun, PM. Immune and inflammatory mechanisms in pulmonary arterial hypertension. Prog Cardiovasc Dis 2012; 55: 218–228.CrossRefGoogle ScholarPubMed
7. Savale, L, Tu, L, Rideau, D, et al. Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir Res 2009; 10: 6.Google Scholar
8. Perros, F, Dorfmüller, P, Souza, R, et al. Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension. Eur Respir J 2007; 29: 937–943.Google Scholar
9. LaFarge, CG, Miettinen, OS. The estimation of oxygen consumption. Cardiovasc Res 1970; 4: 23–30.Google Scholar
10. Rubin, LJ. Pulmonary arterial hypertension. Proc Am Thorac Soc 2006; 3: 111–115.Google Scholar
11. Nathan, C. Points of control in inflammation. Nature 2002; 420: 846–852.Google Scholar
12. Zernecke, A, Weber, C. Inflammatory mediators in atherosclerotic vascular disease. Basic Res Cardiol 2005; 100: 93–101.Google Scholar
13. Raines, EW, Ferri, N. Thematic review series: the immune system and atherogenesis. Cytokines affecting endothelial and smooth muscle cells in vascular disease. J Lipid Res 2005; 46: 1081–1092.Google Scholar
14. Schober, A. Chemokines in vascular dysfunction and remodeling. Arterioscler Thromb Vasc Biol 2008; 28: 1950–1959.Google Scholar
15. Soon, E, Holmes, AM, Treacy, CM, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 2010; 122: 920–927.Google Scholar
16. Gourh, P, Arnett, FC, Assassi, S, et al. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther 2009; 11: R147.Google Scholar
17. Eddahibi, S, Chaouat, A, Tu, L, et al. Interleukin-6 gene polymorphism confers susceptibility to pulmonary hypertension in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006; 3: 475–476.Google Scholar
18. Niu, X, Nouraie, M, Campbell, A, et al. Angiogenic and inflammatory markers of cardiopulmonary changes in children and adolescents with sickle cell disease. PLoS One 2009; 4: e7956.Google Scholar
19. Balabanian, K, Foussat, A, Dorfmüller, P, et al. CX(3)C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med 2002; 165: 1419–1425.Google Scholar
20. Ndrepepa, G, Braun, S, Cassese, S, et al. C-reactive protein and prognosis in women and men with coronary artery disease after percutaneous coronary intervention. Cardiovasc Revasc Med 2013; 14: 264–269.Google Scholar
21. Quarck, R, Nawrot, T, Meyns, B, et al. C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 53: 1211–1218.Google Scholar
22. Scognamiglio, G, Kempny, A, Price, LC, et al. C-reactive protein in adults with pulmonary arterial hypertension associated with congenital heart disease and its prognostic value. Heart 2014; 100: 1335–1341.Google Scholar
23. Elstein, D, Nir, A, Klutstein, M, et al. C-reactive protein and NT-proBNP as surrogate markers for pulmonary hypertension in Gaucher disease. Blood Cells Mol Dis 2005; 34: 201–205.CrossRefGoogle ScholarPubMed
24. Dahl, M, Vestbo, J, Lange, P, et al. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 250–255.Google Scholar
25. Joppa, P, Petrasova, D, Stancak, B, et al. Systemic inflammation in patients with COPD and pulmonary hypertension. Chest 2006; 130: 326–333.Google Scholar